Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
76.83(c) 78.68(c) 79.02(c) 80.5(c) 81.75(c) Last
873 291 1 093 804 826 956 1 294 424 1 465 863 Volume
-0.48% +2.41% +0.43% +1.87% +1.55% Change
More quotes
Financials (USD)
Sales 2019 2 063 M
EBIT 2019 435 M
Net income 2019 346 M
Finance 2019 1 766 M
Yield 2019 -
Sales 2020 2 397 M
EBIT 2020 627 M
Net income 2020 512 M
Finance 2020 2 340 M
Yield 2020 -
P/E ratio 2019 58,09
P/E ratio 2020 38,20
EV / Sales2019 7,64x
EV / Sales2020 6,34x
Capitalization 17 530 M
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (77.9%); - royalties (12.5%); - income from research and... 
Sector
Biotechnology & Medical Research
Calendar
06/03 | 09:00amPresentation
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
05/24INCYTE : Summary ToggleFDA Approves Jakafi® (ruxolitinib) for the Treatment of P..
PU
05/24INCYTE : FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with A..
BU
05/23INCYTE : Summary ToggleIncyte to Present at Upcoming Investor Conference
PU
05/23INCYTE : to Present at Upcoming Investor Conference
BU
05/21INCYTE : Data from Incyte's Inflammation and Autoimmunity Portfolio to be featur..
AQ
05/20INCYTE : Summary ToggleData from Incyte's Inflammation and Autoimmunity Portfoli..
PU
05/20INCYTE : Data from Incyte's Inflammation and Autoimmunity Portfolio to be Featur..
BU
05/16INCYTE : Summary ToggleIncyte Announces Abstracts Accepted for Presentation at t..
PU
05/16INCYTE : Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual M..
BU
05/13INCYTE : BriaCell Approves New Board of Directors and Chairman at Annual and Spe..
AQ
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 88,1 $
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Dashyant Dhanak Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION28.56%17 530
IQVIA HOLDINGS INC17.40%26 900
LONZA GROUP24.03%23 473
CELLTRION, INC.--.--%19 604
EXACT SCIENCES CORPORATION48.97%12 511
SEATTLE GENETICS, INC.22.03%11 153